PDCD1 and cancer: Indeed, mJX-594 led to a response to combination anti-PD-1 blocking antibody treatment in one of the most resistant murine cancer cell lines, which did not respond to mJX-594 single therapy or anti-PD-1 single therapy (Supplementary Figure S3) [24].